MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

Search

Schrodinger Inc

Slēgts

SektorsVeselības aprūpe

16.39 -5.37

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

16.38

Max

16.53

Galvenie mērījumi

By Trading Economics

Ienākumi

10M

-33M

Pārdošana

-435K

54M

Peļņas marža

-60.369

Darbinieki

891

EBITDA

10M

-31M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+32.95% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 25. febr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-276M

1.2B

Iepriekšējā atvēršanas cena

21.76

Iepriekšējā slēgšanas cena

16.39

Ziņu noskaņojums

By Acuity

43%

57%

102 / 352 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Schrodinger Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 23. janv. 18:41 UTC

Peļņas

SLB Readies Rapid Expansion in Venezuela -- 2nd Update

2026. g. 24. janv. 09:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 24. janv. 09:20 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2026. g. 24. janv. 09:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 24. janv. 09:20 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 24. janv. 06:18 UTC

Iegādes, apvienošanās, pārņemšana

Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock. -- Barrons.com

2026. g. 23. janv. 22:30 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 23. janv. 22:30 UTC

Tirgus saruna

Trump Seen Using Canada's EV Deal With China to Extract Concessions -- Market Talk

2026. g. 23. janv. 22:03 UTC

Peļņas

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

2026. g. 23. janv. 21:52 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

GE Aerospace's Earnings Worried the Market. What CEO Larry Culp Says. -- Barrons.com

2026. g. 23. janv. 21:50 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2026. g. 23. janv. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 23. janv. 21:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 23. janv. 21:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 23. janv. 21:39 UTC

Peļņas

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 5th Update

2026. g. 23. janv. 21:15 UTC

Iegādes, apvienošanās, pārņemšana

Eaton Completes Acquisition Of Ultra PCS Limited, Expanding Capabilities And Solutions For Next-generation Aerospace And Defense Markets >ETN

2026. g. 23. janv. 21:12 UTC

Peļņas

CSX Stock Rises After Earnings Miss Estimates. It's the Outlook. -- Barrons.com

2026. g. 23. janv. 20:31 UTC

Peļņas

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

2026. g. 23. janv. 20:12 UTC

Tirgus saruna

Oil Futures Rebound on Iran, Russia-Ukraine Risk -- Market Talk

2026. g. 23. janv. 20:07 UTC

Tirgus saruna

U.S. Natural Gas Posts Record Weekly Gain on Winter Storm -- Market Talk

2026. g. 23. janv. 19:36 UTC

Tirgus saruna

Dollar Weakens Against Yen Amid Intervention Chatter -- Market Talk

2026. g. 23. janv. 19:30 UTC

Tirgus saruna
Peļņas

Intel's Stock Has Limited Catalysts Ahead, Analysts Say -- Market Talk

2026. g. 23. janv. 19:18 UTC

Tirgus saruna

Gold and Silver Step Up to More Records -- Market Talk

2026. g. 23. janv. 19:15 UTC

Peļņas

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 4th Update

2026. g. 23. janv. 18:53 UTC

Tirgus saruna

U.S. Oil Rig Count Rises By 1 to 411 -- Market Talk

2026. g. 23. janv. 18:21 UTC

Peļņas

Week's Best: Schwab's Assets and Profits Keep Climbing -- Barrons.com

2026. g. 23. janv. 18:19 UTC

Tirgus saruna

Intel Seen as Increasingly Confident on Demand -- Market Talk

2026. g. 23. janv. 17:59 UTC

Peļņas

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 3rd Update

2026. g. 23. janv. 17:57 UTC

Tirgus saruna

Intel Could Sign Deals With Big Tech Players for 14A -- Market Talk

2026. g. 23. janv. 17:57 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Schrodinger Inc Prognoze

Cenas mērķis

By TipRanks

32.95% augšup

Prognoze 12 mēnešiem

Vidējais 21.83 USD  32.95%

Augstākais 25 USD

Zemākais 18 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Schrodinger Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

7 ratings

4

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

23.27 / 26.13Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Very Strong Bullish Evidence

Ilgtermiņā

Very Strong Bullish Evidence

Noskaņojums

By Acuity

102 / 352 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
help-icon Live chat